GlaxoSmithKline’s (GSK) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reissued their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report sent to investors on Tuesday.

GSK has been the topic of several other reports. Berenberg Bank upped their target price on GlaxoSmithKline from GBX 1,780 ($23.04) to GBX 1,790 ($23.17) and gave the company a buy rating in a research report on Wednesday, April 25th. Credit Suisse Group set a GBX 1,450 ($18.77) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Monday, July 16th. UBS Group reissued a buy rating and issued a GBX 1,700 ($22.01) target price (up from GBX 1,600 ($20.71)) on shares of GlaxoSmithKline in a research report on Monday, July 30th. Deutsche Bank set a GBX 1,525 ($19.74) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Monday, July 9th. Finally, Kepler Capital Markets set a GBX 1,440 ($18.64) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 1,541.74 ($19.96).

LON GSK opened at GBX 1,575.60 ($20.40) on Tuesday. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($15.99) and a 1 year high of GBX 1,724.50 ($22.32).

The business also recently declared a dividend, which will be paid on Thursday, October 11th. Shareholders of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 9th.

In other GlaxoSmithKline news, insider David Redfern sold 1,925 shares of the stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.39), for a total transaction of £30,318.75 ($39,247.57). Also, insider Philip R. Hampton purchased 2,810 shares of the business’s stock in a transaction on Wednesday, July 25th. The shares were bought at an average cost of GBX 1,557 ($20.16) per share, for a total transaction of £43,751.70 ($56,636.50).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply